Literature DB >> 12401443

Persephin-overexpressing neural stem cells regulate the function of nigral dopaminergic neurons and prevent their degeneration in a model of Parkinson's disease.

P Akerud1, P C Holm, G Castelo-Branco, K Sousa, F J Rodriguez, E Arenas.   

Abstract

Persephin (PSP) is a neurotrophic factor of the GDNF family that has been found to promote the survival of multiple populations of neurons. In the present study we have examined: (1) the mechanism of action and the function of PSP on nigrostriatal dopamine neurons and (2) the therapeutic potential of PSP, delivered by neural stem cells (NSCs) in a model of Parkinson's disease. Interestingly we found that the prenatal ventral mesencephalon and the newborn striatum express high levels of PSP mRNA. Moreover, midbrain dopamine neurons express its preferred receptor GFRalpha4, allowing a cis type of action of PSP on dopamine neurons. Primary culture studies showed that PSP is as potent and efficacious as GDNF at promoting both survival and neuritogenesis of midbrain dopamine neurons. To study the function and therapeutic potential of PSP in vivo we engineered NSCs to overexpress PSP. PSP-c17.2 cells were found to stably express PSP mRNA and protein for at least 3 months in vivo, to disperse within the striatum, and to give rise to neurons, astrocytes, and a large proportion of oligodendrocytes that integrated within white matter tracts in the striatum. Moreover, PSP-c17.2 cells enhanced dopamine-dependent behavioral parameters in unlesioned mice and prevented the loss of dopamine neurons and the behavioral impairment of mice receiving intrastriatal 6-OHDA injections. Thus, our findings are consistent with a direct action of PSP on developing and adult midbrain dopamine neurons and suggest that the delivery of PSP by NSCs may constitute a very useful strategy in the treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401443     DOI: 10.1006/mcne.2002.1171

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  14 in total

1.  The first cysteine-rich domain of the receptor GFRalpha1 stabilizes the binding of GDNF.

Authors:  Heidi Virtanen; Jianmin Yang; Maxim M Bespalov; Jukka O Hiltunen; Veli-Matti Leppänen; Nisse Kalkkinen; Adrian Goldman; Mart Saarma; Pia Runeberg-Roos
Journal:  Biochem J       Date:  2005-05-01       Impact factor: 3.857

2.  Viability-dependent promoting action of adult neural precursors in spinal cord injury.

Authors:  Daniele Bottai; Laura Madaschi; Anna M Di Giulio; Alfredo Gorio
Journal:  Mol Med       Date:  2008 Sep-Oct       Impact factor: 6.354

Review 3.  Roles for the TGFβ superfamily in the development and survival of midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2014-02-07       Impact factor: 5.590

Review 4.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

5.  Surgical management of Parkinson's disease: update and review.

Authors:  Y Chao; L Gang; Z L Na; W Y Ming; W S Zhong; W S Mian
Journal:  Interv Neuroradiol       Date:  2008-02-01       Impact factor: 1.610

Review 6.  Neurotrophic Factors and Their Potential Applications in Tissue Regeneration.

Authors:  Nan Xiao; Quynh-Thu Le
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-11-26       Impact factor: 4.291

Review 7.  Gene regulatory networks in embryonic stem cells and brain development.

Authors:  Dhimankrishna Ghosh; Xiaowei Yan; Qiang Tian
Journal:  Birth Defects Res C Embryo Today       Date:  2009-06

Review 8.  Treatment of Parkinson's disease with trophic factors.

Authors:  Amie L Peterson; John G Nutt
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

9.  Stem cell therapy for Parkinson's disease.

Authors:  Lars M Björklund
Journal:  Dialogues Clin Neurosci       Date:  2004-09       Impact factor: 5.986

10.  Dopaminergic regeneration by neurturin-overexpressing c17.2 neural stem cells in a rat model of Parkinson's disease.

Authors:  Wei-Guo Liu; Xi-Jing Wang; Guo-Qiang Lu; Biao Li; Gang Wang; Sheng-Di Chen
Journal:  Mol Neurodegener       Date:  2007-10-01       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.